SML3852
Saroglitazar Magnesium
≥98% (HPLC)
别名:
(αS)-α-Ethoxy-4-[2-[2-methyl-5-[4-(methylthio)phenyl]-1H-pyrrol-1-yl]ethoxy]benzenepropanoic acid Magnesium, (s)-2-Ethoxy-3-(4-(2-(2-methyl-5-(4-(methylthio)phenyl)-1H-pyrrol-1-yl)ethoxy)phenyl)propanoic acid Magnesium
SMILES string
[Mg+2].S(C)c4ccc(cc4)c5[n](c(cc5)C)CCOc6ccc(cc6)C[C@H](OCC)C(=O)[O-].S(C)c1ccc(cc1)c2[n](c(cc2)C)CCOc3ccc(cc3)C[C@H](OCC)C(=O)[O-]
InChI key
UJYFZCVPOSZDMK-YPPDDXJESA-L
InChI
1S/2C25H29NO4S.Mg/c2*1-4-29-24(25(27)28)17-19-6-10-21(11-7-19)30-16-15-26-18(2)5-14-23(26)20-8-12-22(31-3)13-9-20;/h2*5-14,24H,4,15-17H2,1-3H3,(H,27,28);/q;;+2/p-2/t2*24-;/m00./s1
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear (Warmed)
storage temp.
-10 to -25°C
Quality Level
Biochem/physiol Actions
Potent and selective PPARα/γ agonist.
Saroglitazar is a potent and selective PPARα/γ (peroxisome proliferator-activated receptor) agonist that exhibits lipid-lowering and insulin-sensitizing effects. Saroglitazar is approved in India for the treatment of diabetes type 2 and dyslipidemia.
Saroglitazar is a potent and selective PPARα/γ (peroxisome proliferator-activated receptor) agonist that exhibits lipid-lowering and insulin-sensitizing effects. Saroglitazar is approved in India for the treatment of diabetes type 2 and dyslipidemia.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Saroglitazar, a novel dual PPAR-?/? agonist, reverses high fat-low protein diet-induced metabolic and cognitive aberrations in C57BL/6J male mice
Life Sciences, 271, 119191-119191 (2021)
Saroglitazar, a novel PPAR?/? agonist with predominant PPAR? activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models
Pharmacology Research & Perspectives, 3(3) (2015)
Saroglitazar reduces obesity and associated inflammatory consequences in murine adipose tissue
European Journal of Pharmacology, 822, 32-42 (2018)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持